23 completed, 10 recruiting, 4 withdrawn, 2 terminated. 27 Phase 2, 8 Phase 1, 6 Phase 3, 2 Phase 4.
Follow Rigel Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults Placebo, Fostamatinib - Acute Respiratory Distress Syndrome, ARDS | Phase 2 | Not yet recruiting | Inova Health Care Services | 40 | 2026-11-30 | 2026-10-27 |
| Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax Olutasidenib, Azacitidine (AZA) - IDH1 Mutation, Relapsed / Refractory AML | Phase 2 | Recruiting | Timothy Pardee | 25 | 2026-11-01 | 2026-11-04 |
| Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy Olutasidenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, IDH1 Mutation | Phase 2 | Recruiting | Justin Watts, MD | 16 | 2026-03-31 | 2026-04-16 |
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies Olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates - AML (Acute Myeloid Leukemia), Glioma | Phase 4 | Recruiting | Rigel Pharmaceuticals | 16 | 2026-02-23 | 2026-08-11 |
| Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation Olutasidenib Investigational Agent Administration - Acute Myeloid Leukemia | Phase 1 | Withdrawn | Virginia Commonwealth University | 2026-02-02 | 2026-10-29 | |
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD Fostamatinib, Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | Stefanie Sarantopoulos, MD, PhD. | 30 | 2025-10-29 | 2026-01-22 |
| Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations Olutasidenib, Cladribine (CLAD), Venetoclax - Targeted Therapy, IDH1-Mutated Malignancies | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 68 | 2025-09-12 | 2026-10-05 |
| Study of Olutasidenib and Temozolomide in HGG Olutasidenib + TMZ - High Grade Glioma, Astrocytoma | Phase 2 | Recruiting | Rigel Pharmaceuticals | 60 | 2025-02-01 | 2026-09-01 |
| A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm Olutasidenib - Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-01-28 | 2026-10-05 | |
| A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. Olutasidenib - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2024-12-10 | 2026-09-11 |
| Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | University of California, San Diego | 36 | 2024-12-05 | 2026-04-07 |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis LY3871801, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Eli Lilly and Company | 164 | 2023-05-23 | 2026-05-22 |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) R906289 Monosodium (R289 Na) - Low Risk Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Rigel Pharmaceuticals | 86 | 2022-09-12 | 2026-08-10 |
| Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa Fostamatinib - Hidradenitis Suppurativa | Phase 2 | Completed | Holdsworth House Medical Practice | 20 | 2021-10-01 | 2023-03-01 |
| Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy Fostamatinib - ITP, Immune Thrombocytopenia | Terminated | Rigel Pharmaceuticals | 16 | 2021-05-18 | 2024-03-15 | |
| Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia Fostamatinib, Ruxolitinib - Myelofibrosis, Thrombocytopenia | Phase 2 | Terminated | Washington University School of Medicine | 3 | 2021-05-03 | 2023-12-15 |
| Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects Fostamatinib, Placebo - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Completed | Rigel Pharmaceuticals | 280 | 2021-03-25 | 2023-08-18 |
| Inflammatory Signal Inhibitors for COVID-19 (MATIS) Ruxolitinib, Fostamatinib, Standard of care - Coronavirus, Covid19 | Phase 1 / Phase 2 | Completed | Imperial College London | 185 | 2020-10-02 | 2025-11-18 |
| A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Fostamatinib disodium - Warm Antibody Autoimmune Hemolytic Anemia | Phase 3 | Enrolling by invitation | Rigel Pharmaceuticals | 90 | 2019-10-30 | 2022-03-17 |
Showing 20 of 42. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (6) · Arthritis, Rheumatoid (4) · Leukemia, Myeloid, Acute (4) · Keratoconjunctivitis Sicca (3) · Bronchiolitis Obliterans Syndrome (2) · COVID-19 (2) · Glioma (2) · Glomerulonephritis, IGA (2) · Leukemia, Myelomonocytic, Chronic (2) · Lupus Erythematosus, Systemic (2) · Lymphoma (2) · Myelodysplastic Syndromes (2) · Neoplasms (2) · Pneumonia (2) · Asthma (1)
fostamatinib (25) · olutasidenib (7) · ruxolitinib (4) · Azacitidine (2) · BID protein, human (2) · Cytochrome P-450 CYP2C8 (2) · Cytochrome P-450 CYP3A (2) · venetoclax (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Beclomethasone (1) · Cladribine (1) · Cytarabine (1) · Cytochrome P-450 CYP1A2 (1) · Cytochrome P-450 CYP2B6 (1)
United States (32) · Canada (8) · United Kingdom (8) · Germany (7) · Australia (6) · Austria (5) · Bulgaria (5) · Czechia (5) · Italy (5) · Netherlands (5) · Spain (5) · France (4) · Hungary (4) · Mexico (4) · Norway (4)
Daniel B Magilavy, MD (2) · Daniel Magilavy, MD (2) · Elliott Grossbard, M.D. (2) · Jeffrey Skolnik, MD (2) · Kelly Chien, MD (2) · Amy Zhou, M.D. (1) · Andrew Lowy, MD (1) · Anne-Marie Duliege, M.D. (1) · Arthur Kavanaugh, M.D. (1) · Chenyu Lin, MD (1) · Christopher S. King, MD, FACP (1) · Courtney DiNardo, MD (1) · Daniel B. Magilavy, MD (1)
PMID 33995988, PMID 19096013, PMID 19965662, PMID 20879879, PMID 26032537, PMID 30177021, PMID 33687069, PMID 33845867, PMID 34124781, PMID 34473343, PMID 35179251, PMID 37522746, PMID 41644167
2008 (1), 2014 (1)